Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
AEOLUS PHARMACEUTICALS, INC. (AOLS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/22/2017 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/14/2017 |
10-Q
| Quarterly Report for the period ended June 30, 2017 |
| 05/15/2017 |
10-Q
| Quarterly Report for the period ended March 31, 2017 |
| 03/24/2017 |
8-K
| Quarterly results |
| 02/17/2017 |
10-Q
| Quarterly Report for the period ended December 31, 2016 |
| 02/14/2017 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB |
| 01/30/2017 |
10-K/A
| Annual Report for the period ended September 30, 2016 [amend] |
| 12/30/2016 |
4
| McManus John L (President and CEO) has filed a Form 4 on AEOLUS PHARMACEUTICALS, INC.|
Txns:
| Granted 25,000 shares
@ $0.15, valued at
$3.8k
Granted 250,000 options to buy
@ $0.1855, valued at
$46.4k
|
|
| 12/20/2016 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 12/20/2016 |
10-K
| Annual Report for the period ended September 30, 2016 |
| 09/13/2016 |
8-K
| Form 8-K - Current report |
| 08/15/2016 |
10-Q
| Quarterly Report for the period ended June 30, 2016 |
| 05/26/2016 |
8-K
| Form 8-K - Current report |
| 05/16/2016 |
10-Q/A
| Quarterly Report for the period ended March 31, 2016 [amend] |
| 05/13/2016 |
10-Q
| Quarterly Report for the period ended March 31, 2016 |
| 04/19/2016 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 03/23/2016 |
PRE 14C
| Form PRE 14C - Other preliminary information statements |
| 02/23/2016 |
8-K
| Form 8-K - Current report |
| 02/16/2016 |
10-Q
| Quarterly Report for the period ended December 31, 2015 |
| 02/16/2016 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2016 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend] |
| 02/08/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/03/2016 |
4
| KUMAR AMIT (Director) has filed a Form 4 on AEOLUS PHARMACEUTICALS, INC.|
Txns:
| Granted 100,000 options to buy
@ $0.2612, valued at
$26.1k
Granted 100,000 options to buy
@ $0.24, valued at
$24k
Granted 100,000 options to buy
@ $0.25, valued at
$25k
|
|
| 01/26/2016 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933 |
| 12/18/2015 |
10-K
| Annual Report for the period ended December 14, 2015 |
| 12/15/2015 |
8-K
| Form 8-K - Current report |
| 12/15/2015 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 10/05/2015 |
8-K
| Form 8-K - Current report |
| 08/14/2015 |
10-Q
| Quarterly Report for the period ended June 30, 2015 |
| 05/15/2015 |
10-Q
| Quarterly Report for the period ended March 31, 2015 |
| 05/04/2015 |
8-K
| Form 8-K - Current report |
| 02/17/2015 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Aeolus Pharmaceuticals, Inc. |
| 02/13/2015 |
10-Q
| Quarterly Report for the period ended December 31, 2014 |
| 02/13/2015 |
10-K/A
| Annual Report for the period ended September 30, 2014 [amend] |
|
|
|